Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01202331
Other study ID # 10-02169
Secondary ID
Status Completed
Phase Phase 4
First received September 13, 2010
Last updated October 9, 2017
Start date November 2010
Est. completion date May 2014

Study information

Verified date October 2017
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mass antimicrobial administrations have been remarkably successful in reducing the prevalence of the ocular strains of Chlamydia that cause trachoma. Repeated distributions progressively lower the prevalence of infection, and in some cases may even result in local elimination. Mass treatments cannot be continued forever, due to concerns about cost and antibiotic resistance. The hope has been that other measures such as latrine construction and hygiene programs would prevent infection from returning. Unfortunately, no non-antibiotic measure has yet demonstrated an effect on infection.

1. We hypothesize that Chlamydial infection will return to communities when treatment ends.

2. We hypothesize that infection will be completely eliminated in all communities treated for seven years.

3. We hypothesize that identifying and treating clinically active cases among preschool aged children will delay or even prevent reemergence at a far lower cost than mass treatment of all individuals.


Description:

The proposed study is a group-randomized trial to determine the frequency and treatment target of community-wide mass antibiotic treatment to eliminate trachoma. We will continue to monitor a sub-set of communities from our TANA study, in Goncha Siso Enese district of East Gojam Zone, Ethiopia. Here we evaluate how infection returns when antibiotics are discontinued, whether infection can be predictably eliminated, and whether infection can be prevented from returning with targeted treatment strategies:

Specific Aim 1. To determine whether antibiotics can be stopped after 4 years.

Specific Aim 2. To determine whether infection can be completely eliminated if mass treatments continue for seven years.

Specific Aim 3. To determine whether treatment targeted to pre-school aged children, or to households in which a pre-school aged child has clinically active trachoma, will prevent infection from returning into the community.

Specific Aim 4: To determine whether mass azithromycin distributions reduce visits to local health clinics due to all causes and infectious causes.

Specific Aim 5: To determine whether mass azithromycin distributions result in better growth metrics (weight-for-height, height-for age, weight-for-age, middle upper arm circumference) compared to no treatment.

Specific Aim 6: To determine whether under-5 mortality is lower in communities treated with mass azithromycin compared to no treatment

Specific Aim 7: To determine whether macrolide resistance in Streptococcus pneumoniae, Hameophilus influenzae, and Staphylococcus aureus is more prevalent in communities treated with biannual mass azithromycin compared to communities treated with annual mass azithromycin, and to determine whether targeted azithromycin treatments result in less macrolide resistance compared to mass azithromycin distributions.


Recruitment information / eligibility

Status Completed
Enrollment 29000
Est. completion date May 2014
Est. primary completion date November 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- All residents residing in the state-teams which are randomly selected for this study.

Exclusion Criteria:

- Pregnant women

- Children under 6 months of age

- All those who are allergic to macrolides or azalides

- Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

Individuals in these three exclusion criteria will not be given the study antibiotic azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day, topically to both eyes, for six weeks. Note that the exclusion criteria refer to the exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and examinations.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
mass treatment with oral azithromycin
For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.

Locations

Country Name City State
Ethiopia The Carter Center, Ethiopia Addis Ababa

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

Ethiopia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The average prevalence of ocular chlamydia infection in communities in an arm as determined by pooled NAAT (Nucleic Acid Amplification Test)(at 36 months versus 0 months for Aim 1, at 36 months for Aim 2 and Aim 3) 36 months
Secondary Clinical active trachoma in community, as determined by the WHO simplified grading system 36 months
Secondary Childhood mortality (6 months -5 years of age), 6-10 years of age, and >10 years 36 months
Secondary Macrolide resistance in pneumococcus, Haemophilus influenzae, and Staphylococcus aureus (% resistance over time, clustered by randomization unit) 36 months
Secondary Anthropometric measurements (weight and height), as outlined by WHO child growth standards (0-5 years of age) 3, 12, 24, and 36 months after baseline
Secondary Health clinic visits (due to all causes and due to infectious causes) in children aged 6 months-5 years, 6-10 years, and >10 years 36 months
Secondary Prevalence of anemia (hemoglobin levels in 0-9 year olds) and the prevalence of malaria 36 months
Secondary Clinically active trachoma in a school (all children under age 10), as determined by the WHO simplified grading system 36 months
Secondary Cost-effectiveness of mass azithromycin administration, per infection year prevented and cost per eliminated village 0, 12, 24, and 36 months
Secondary Estimate of chlamydial load from real-time, qPCR 0, 12, 24, 36 months
See also
  Status Clinical Trial Phase
Completed NCT02493647 - Love, Sex & Choices: A Web Series on Mobile Devices to Reduce Black Women's HIV Risk N/A
Completed NCT01439503 - Safer Sex Program for Young African-American Men Phase 2
Completed NCT01140022 - Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia N/A
Not yet recruiting NCT06428643 - A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities N/A
Completed NCT03896776 - A Pragmatic Trial of Two Strategies for Implementing an Effective eHealth HIV Prevention Program (Keep It Up! 3.0) N/A
Completed NCT00187902 - Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM N/A
Completed NCT04553068 - Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection Phase 3
Active, not recruiting NCT03980223 - Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Phase 4
Completed NCT01465607 - Implementation of an Efficacious Intervention for High Risk Women in Mexico N/A
Completed NCT01596946 - Home-sampling in Partner Notification of Chlamydia N/A
Completed NCT02122094 - Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities N/A
Completed NCT01836445 - Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men N/A
Completed NCT00827697 - A Validation Study for Detecting Chlamydia and Gonorrhea in Rectal Samples N/A
Completed NCT02019771 - Gonorrhea and Chlamydia HIV-infected Men Who Have Sex With Men
Completed NCT00221364 - Trachoma Elimination Follow-up Phase 4
Completed NCT00140296 - Using the Healthcare Visit to Improve Contraceptive Use N/A
Recruiting NCT06187064 - Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington N/A
Completed NCT03895320 - Protecting Our Future Generation: Promotion of Protective Sexual Health Practices Among Native American Youth and Young Adults Through an Assets-based Self-care Intervention N/A
Completed NCT02055742 - Detection of Chlamydia (CT) and Gonorrhea (NG) N/A
Completed NCT03090802 - MAMAS: Mentoring Adolescent Mothers at School N/A